Viruria Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection. Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens: - 10 mg BCV administered twice weekly (BIW) on Days 0, 3, 7, 10, 14. - 20 mg BCV administered once weekly (QW) on Days 0, 7, and 14 and placebo administered on Days 3 or 10. - Placebo administered BIW on Days 0, 3, 7, 10 ,14. - 40 mg BCV administered QW on Days 0, 7, 14, 21, and 28. - Placebo administered QW on Days 0, 7, 14, 21, and 28. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01620268 -
An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
|
Phase 2 |